|
64 Companies |
|
72 Products |
|
72 Products |
|
70 Mechanisms of Action |
|
1 Trial |
|
336 News |
|
| «1234567» |
- ||| figitumumab (CP-751,871) / Novartis
Trial completion, Metastases: Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors (clinicaltrials.gov) - Dec 18, 2012
P1, N=65, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed
- thiotepa / Generic mfg.
Enrollment open: OSII-TTP: Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma (clinicaltrials.gov) - Dec 16, 2012
P2, N=66, Recruiting, Sponsor: Centre Leon Berard
Active, not recruiting --> Completed Suspended --> Recruiting
- ||| saridegib oral (IPI 926 oral) / Infinity Pharma
Enrollment change, Metastases: A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma (clinicaltrials.gov) - Dec 6, 2012
P2, N=105, Completed, Sponsor: Infinity Pharmaceuticals, Inc.
Suspended --> Recruiting N=140 --> 105
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment closed, Metastases: Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma (clinicaltrials.gov) - Dec 4, 2012
P2, N=24, Active, not recruiting, Sponsor: Massachusetts General Hospital
N=140 --> 105 Recruiting --> Active, not recruiting
- || Enrollment change, Metastases: Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Nov 29, 2012
P1, N=121, Completed, Sponsor: TopoTarget A/S
Recruiting --> Active, not recruiting N=100 --> 121
- ||| Trial completion, Metastases: Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Nov 29, 2012
P1, N=121, Completed, Sponsor: TopoTarget A/S
N=100 --> 121 Active, not recruiting --> Completed
- || New P3 trial: Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients (clinicaltrials.gov) - Nov 26, 2012
P3, N=150, Recruiting, Sponsor: Children's Cancer Hospital Egypt 57357
- |||| figitumumab (CP-751,871) / Pfizer
Trial completion: Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors (clinicaltrials.gov) - Nov 7, 2012
P1/2, N=138, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Nov 7, 2012
P2, N=7, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=44 --> 7
- Trial completion, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Nov 7, 2012
P2, N=7, Completed, Sponsor: City of Hope Medical Center
N=44 --> 7 Active, not recruiting --> Completed
- Talzenna (talazoparib) / Pfizer
Enrollment change, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Nov 5, 2012
P1, N=85, Recruiting, Sponsor: BioMarin Pharmaceutical
Active, not recruiting --> Completed N=70 --> 85
- Enrollment change: Physical Characteristics of Retrieved Massive Allografts (clinicaltrials.gov) - Oct 25, 2012
P4, N=18, Completed, Sponsor: University of Florida
N=70 --> 85 N=30 --> 18
- Enrollment change: HLA Sensitization Following Major Cortical Allograft Bone Procedures (clinicaltrials.gov) - Oct 25, 2012
P4, N=10, Completed, Sponsor: University of Florida
N=30 --> 18 N=120 --> 10
- Trial completion: Physical Characteristics of Retrieved Massive Allografts (clinicaltrials.gov) - Oct 25, 2012
P4, N=18, Completed, Sponsor: University of Florida
N=120 --> 10 Active, not recruiting --> Completed
- Trial completion: HLA Sensitization Following Major Cortical Allograft Bone Procedures (clinicaltrials.gov) - Oct 25, 2012
P4, N=10, Completed, Sponsor: University of Florida
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
New P2 trial, Surgery: GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) - Sep 27, 2012
P2, N=43, Recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=24, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=45 --> 24
- Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=24, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=45 --> 24 Recruiting --> Completed
- etoposide oral / Generic mfg., cisplatin / Generic mfg.
Trial termination, Metastases: Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor (clinicaltrials.gov) - Sep 19, 2012
P2, N=3, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Sep 19, 2012
P3, N=214, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Completed
- Trial completion, Surgery, Metastases: MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors (clinicaltrials.gov) - Sep 12, 2012
P1, N=10, Completed, Sponsor: InSightec
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy (clinicaltrials.gov) - Sep 5, 2012
P=N/A, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change, Metastases: Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain (clinicaltrials.gov) - Aug 19, 2012
P2, N=1, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Recruiting N=40 --> 1
- | lithium carbonate ER / Generic mfg.
New P4 trial: Li2CO3: Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma (clinicaltrials.gov) - Aug 19, 2012
P4, N=400, Not yet recruiting, Sponsor: Sun Yat-sen University
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment change: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Jul 19, 2012
P1, N=75, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=40 --> 1 N=45 --> 75
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - Jul 17, 2012
P2, N=172, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=45 --> 75 Recruiting --> Active, not recruiting
- Trial completion, Metastases: Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 16, 2012
P2, N=39, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed, HEOR, Surgery: Cyberknife Radiosurgery and Quality of Life (clinicaltrials.gov) - Jul 15, 2012
P=N/A, N=70, Active, not recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| ThermoDox + HIFU / Celsion
New P2 trial: MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases (clinicaltrials.gov) - Jul 12, 2012
P2, N=52, Not yet recruiting, Sponsor: Celsion
- calcitriol (BPM 31543) / BPGbio
Enrollment open, Metastases: Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease (clinicaltrials.gov) - Jul 2, 2012
P1, N=18, Recruiting, Sponsor: Berg Pharma,LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enbrel (etanercept) / Pfizer, Amgen
Trial termination: Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia (clinicaltrials.gov) - Jun 21, 2012
P2/3, N=54, Terminated, Sponsor: The University of Texas Health Science Center at San Antonio
Not yet recruiting --> Recruiting Recruiting --> Terminated; PI moved to Oregon
- Trial completion: Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor (clinicaltrials.gov) - Jun 12, 2012
P1, N=37, Completed, Sponsor: University of Medicine and Dentistry New Jersey
Recruiting --> Terminated; PI moved to Oregon Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
New P2 trial, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jun 6, 2012
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- New P1/2 trial: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (clinicaltrials.gov) - May 31, 2012
P1/2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
- exatecan mesylate (DX-8951f) / Daiichi Sankyo
Trial completion: Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor (clinicaltrials.gov) - May 14, 2012
P2, N=0, Completed, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Vaxira (racotumomab) / Eurofarma, Recombio
New P1 trial: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides (clinicaltrials.gov) - May 13, 2012
P1, N=15, Recruiting, Sponsor: Laboratorio Elea S.A.C.I.F. y A.
- Trial initiation date: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - May 7, 2012
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Active, not recruiting --> Completed Initiation date: Dec 2011 --> May 2012
- |||| cixutumumab (IMC A12) / Eli Lilly
Trial completion, Metastases: A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma (clinicaltrials.gov) - May 7, 2012
P2, N=111, Completed, Sponsor: ImClone LLC
Initiation date: Dec 2011 --> May 2012 Active, not recruiting --> Completed
- calcitriol (BPM 31543) / BPGbio
New P1 trial, Metastases: Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease (clinicaltrials.gov) - Apr 29, 2012
P1, N=18, Recruiting, Sponsor: Berg Pharma,LLC
- | Lonquex (lipegfilgrastim biosimilar) / Teva
New P1 trial: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma (clinicaltrials.gov) - Apr 24, 2012
P1, N=21, Recruiting, Sponsor: Merckle GmbH
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P2 trial, Metastases: Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma (clinicaltrials.gov) - Apr 22, 2012
P2, N=24, Active, not recruiting, Sponsor: Massachusetts General Hospital
- Enrollment closed, Metastases: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants (clinicaltrials.gov) - Apr 16, 2012
P=N/A, N=48, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | zoledronic acid / Generic mfg.
Trial completion, Metastases: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma (clinicaltrials.gov) - Apr 16, 2012
P=N/A, N=24, Completed, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting Suspended --> Completed
- gefitinib / Generic mfg.
Enrollment change: ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors (clinicaltrials.gov) - Apr 15, 2012
P1, N=19, Completed, Sponsor: St. Jude Children's Research Hospital
Suspended --> Completed N=30 --> 19
- | gefitinib / Generic mfg.
Trial completion: ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors (clinicaltrials.gov) - Apr 15, 2012
P1, N=19, Completed, Sponsor: St. Jude Children's Research Hospital
N=30 --> 19 Recruiting --> Completed
- sirolimus / Generic mfg.
Enrollment open: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Mar 25, 2012
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination, Metastases: Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain (clinicaltrials.gov) - Mar 20, 2012
P2, N=1, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Recruiting Completed --> Terminated; Study was terminated due to poor accrual.
- TXA-127 / Constant Therap
New P2 trial, Surgery, Metastases: Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 12, 2012
P2, N=20, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
- || dactinomycin / Generic mfg., vincristine / Generic mfg.
Biomarker, Enrollment closed: Evaluating Dactinomycin and Vincristine in Young Patients With Cancer (clinicaltrials.gov) - Feb 27, 2012
P=N/A, N=158, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Terminated; Study was terminated due to poor accrual. Suspended --> Active, not recruiting
- robatumumab (SCH 717454) / Merck (MSD)
Trial termination, Combination therapy, Metastases: A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) (clinicaltrials.gov) - Feb 20, 2012
P1, N=4, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Suspended --> Active, not recruiting Completed --> Terminated; Study was terminated for business reasons.